Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.77 +1.63%

+$0.10 today

Market cap
$546.32M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.21M

Average 4.86M

WVE Account Payables

Amounts the company owes suppliers for goods and services received.

Wave Life Sciences Ltd.NASDAQ: WVE

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 32.8% from a year ago

Account payables stood at $19.06M at the end of Q1 FY2026, up 32.8% from a year earlier and up 21.4% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.

Context

  • Account payables amounted to 3.3% of total assets at the end of Q1 FY2026, down 1.7 pp from a year earlier.
  • Account payables increased in 1 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +32.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.06M+21.4% QoQ
Last fiscal yearDec 2025
$15.7M-3.5% YoY
Year agoMar 2025
$14.36M+32.8% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.8%——
1 year-3.5%——
3-year CAGR-2.5%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
15.7M USD
Year-over-year change
-3.5%
4-year CAGR
+21.2%

Account Payables vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +32.8% is the 6th highest of 11, against a peer median of +26.1%.
  • Account payables amounts to 3.3% of total assets for WVE, versus a peer median of 1.7%.
WVE Competitors
Account Payables for WVE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$108.02M USD+5.5%+5.7%1.9%
SRPTSarepta Therapeutics, Inc.Mar 2026$70.38M USD-54.9%+43.1%2.2%
ARWRArrowhead Pharmaceuticals, Inc.Sep 2026$30.15M USD+70.6%-5.6%1.7%
IONSIonis Pharmaceuticals, Inc.Sep 2026$27.11M USD+89.3%+16.2%0.9%
WVEWave Life Sciences Ltd.Mar 2026$19.06M USD+32.8%-2.5%3.3%
NTLAIntellia Therapeutics, Inc.Mar 2026$18.8M USD+52.1%+57.8%2.5%
SLNSilence Therapeutics plcMar 2026$10.37M USD-44.9%+11.4%9.0%
STOKStoke Therapeutics, Inc.Mar 2026$6.84M USD+212.9%+86.1%1.5%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$4.09M USD-33.8%-17.2%1.7%
BNTCBenitec Biopharma Inc.Mar 2026$635K USD+46.7%-21.9%0.3%
PRQRProQR Therapeutics N.V.Mar 2026€189.2K EUR-57.7%-8.7%0.2%
Peer median (excluding WVE) —+26.1%+8.6%1.7%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents150.56M88.5M200.35M302.08M602.07M
Short-term Investments00000
Net Receivables0021.09M1.42M1.28M
Inventory00000
Other Current Assets5.42M2.11M4.02M7.35M3.08M
Total Current Assets162.56M98.54M235.37M320.39M614.81M
Property, Plant & Equipment (Net)40.64M44.13M35.72M28M19.86M
Goodwill00000
Intangible Assets00000
Long-term Investments00003.81M
Tax Assets00000
Other Non-current Assets3.8M3.72M3.86M3.82M16K
Total Non-current Assets44.44M47.85M39.58M31.81M23.69M
Total Assets207.01M146.39M274.95M352.21M638.5M
Account Payables7.28M16.92M12.84M16.26M15.7M
Short-term Debt00000
Tax Payables00000
Deferred Revenue37.1M31.56M150.06M65.97M44.44M
Other Current Liabilities10.18M12.29M14.07M15.36M18.08M
Total Current Liabilities64.2M71.52M186.44M110.95M95.07M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)77.48M79.77M15.6M6.1M7.8M
Other Non-current Liabilities7.87M8.06M7.87M7.87M0
Total Non-current Liabilities110.31M119.96M48.88M31.74M17.2M
Total Liabilities174.51M191.48M235.32M142.69M112.27M
Common Stock749.85M802.83M935.37M1.18B1.62B
Retained Earnings(805.51M)(967.34M)(1.02B)(1.12B)(1.33B)
Accumulated OCI181K(29K)(124K)(262K)(250K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity32.5M(45.09M)39.63M209.52M526.23M
Total Debt29.92M37.61M32.12M25.4M17.77M
Net Debt(120.65M)(50.88M)(168.23M)(276.67M)(584.3M)

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.